Physician profile
Chakra P Chaulagain
NPI 1487824124
$197,487.93
in general payments reported to CMS, 2019-2025
51 companies · $44K in 2025
The $44K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $10K · 2021: $21K · 2022: $45K · 2023: $38K · 2024: $26K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72K · Consulting Fee: $25K · Food and Beverage: $6,049 · Travel and Lodging: $4,384 · Honoraria: $833 · Education: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $71,705.00 |
| Consulting Fee | $24,760.50 |
| Food and Beverage | $6,049.17 |
| Travel and Lodging | $4,383.93 |
| Honoraria | $832.50 |
| Education | $325.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $74,408.88 | 2019-2025 | Carvykti, Darzalex, Tecvayli |
| Genzyme Corporation | $54,848.91 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $14,828.05 | 2024-2025 | Lynozyfic, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $10,753.89 | 2022-2025 | Sprycel, Reblozyl |
| Pfizer INC. | $8,352.88 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $3,979.94 | 2021-2025 | Darzalex, Pipeline, Balversa |
| Incyte Corporation | $3,417.96 | 2023-2025 | Monjuvi, Pemazyre, Jakafi |
| Beigene USA, INC. | $3,410.08 | 2021-2024 | Brukinsa |
| Geron Corporation | $3,380.53 | 2025 | Imetelstat |
| Agios Pharmaceuticals, INC. | $2,786.40 | 2022-2023 | Pyrukynd |
| Apellis Pharmaceuticals, INC. | $2,377.64 | 2022-2023 | Empaveli |
| Blueprint Medicines Corporation | $2,340.00 | 2020 | |
| Seagen INC. | $1,938.62 | 2019-2023 | Padcev |
| Cti Biopharma Corp. | $1,747.85 | 2022-2023 | Vonjo |
| Karyopharm Therapeutics INC. | $1,550.00 | 2020 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Global Services, LLC | $1,500.00 | 2021 | |
| Epizyme, INC. | $1,250.00 | 2021 | |
| Rigel Pharmaceuticals, INC. | $1,020.33 | 2020-2022 | |
| Janssen Research & Development, LLC | $745.42 | 2024 | Tecvayli |
| Astrazeneca Pharmaceuticals Lp | $676.47 | 2023-2025 | Calquence, Wainua |
| Glaxosmithkline, LLC. | $490.21 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Novartis Pharmaceuticals Corporation | $250.02 | 2021-2025 | |
| Celgene Corporation | $205.96 | 2020-2025 | Pomalyst, Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $197.09 | 2024-2025 | Enhertu, Datroway, Vanflyta |
| Taiho Oncology, INC. | $138.53 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.12 | 2023-2025 | Vpriv, Iclusig, Advate |
| Astellas Pharma US INC | $120.48 | 2022-2025 | Vyloy, Xospata |
| Merck Sharp & Dohme LLC | $64.73 | 2022-2024 | Keytruda, Welireg, Lynparza |
| Abbvie INC. | $60.47 | 2025 | |
| Aurobindo Pharma USA, INC. | $56.86 | 2019-2020 | |
| Tersera Therapeutics LLC | $50.54 | 2024-2025 | Zoladex |
| Stemline Therapeutics INC. | $50.23 | 2024 | Elzonris |
| Emd Serono, INC. | $49.22 | 2023-2024 | Mavenclad |
| Genentech USA, INC. | $41.22 | 2022-2024 | Alecensa, Rozlytrek, Tecentriq |
| Eisai INC. | $31.60 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $24.23 | 2025 | |
| Servier Pharmaceuticals LLC | $23.00 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $21.56 | 2024 | Sancuso |
| Genentech, INC. | $21.33 | 2023 | Tecentriq |
| Tempus Ai, INC | $21.22 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $20.83 | 2023 | Imbruvica, Epkinly |
| Gilead Sciences, INC. | $20.00 | 2025 | Trodelvy |
| Lilly USA, LLC | $17.33 | 2022 | |
| Puma Biotechnology, INC. | $17.23 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.65 | 2023 | |
| Sobi, INC | $14.49 | 2025 | |
| Acrotech Biopharma INC. | $13.93 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chakra Chaulagain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.